Skip to main content
Clinical Trials/NCT00457769
NCT00457769
Unknown
Phase 1

Phase 1 Study of Aricept Plus a Behavioral Strategy to Improve Functional Tasks in Vascular Dementia

Kessler Foundation1 site in 1 country18 target enrollmentMay 2007

Overview

Phase
Phase 1
Intervention
Donepezil and self-generated memory training
Conditions
Stroke
Sponsor
Kessler Foundation
Enrollment
18
Locations
1
Primary Endpoint
Primary: To examine whether taking Aricept results in improvement at remembering steps of functional tasks.
Last Updated
5 years ago

Overview

Brief Summary

Medications for memory improvement are available but they may not actually improve the ability to do real world tasks. The purpose of this research study is to determine if a medicine used to treat memory problems donepezil(Aricept) enhances the ability to remember steps of functional tasks and the actual ability to perform tasks relevant to real-life independence. Aricept is an FDA approved medication for the treatment of Alzheimer's disease. Aricept is an investigational drug for the purposes of this study, and is not approved for this purpose.

Detailed Description

All participants will receive a behavioral intervention as part of the testing protocol: they will be asked to generate words to complete a phrase as they read written steps to perform functional tasks. Mood will be assessed using the Geriatric Depression Scale.(see page 8) Participants will be asked to estimate their memory, immediate attention mood, functional tasks (performing cooking and financial task) and "ability to take medications correctly" (pre-test or "offline" ratings, abstract judgments of their own ability not based directly on performance). They will perform self-assessments of their cognitive, functional abilities and mood using Likert scales. They will mark each of 5 vertical (23.5 cm) lines centered on white paper to indicate their ability. Each line will be labeled for each domain. To estimate of naming ability, show the subject the Likert Scale (attached) for the naming domain. Then explain: "This scale is to measure how well you think your ability to name. Here is the top where you will mark if you think your performance is perfect, here is the bottom if you think you are terrible. You may be somewhere in between. (broadly indicated the whole middle area) mark where you think your performance would belong on this scale". This standard protocol will be used by the examiner in this study to explain each domain with specific types of tasks, and give subjects practical hypothetical examples of good and poor performance. Ability to take medication: Functional memory as applied to medication compliance will be assessed with the Hopkins Medication Schedule (HMS). This test has two part, HMS and pill box. The test will serve as a good evaluation of subject's functional memory, which we suspect it will be most strongly affected by Anosognosia. The HMS: the participant was read (and read along with) a hypothetical scenario in which her physician gave her 1 prescription for an antibiotic and for aspirin to treat an infection along with directions for taking each. The participant was then asked to plan a schedule for taking these medications and water during the course of a day, following the instructions provided.

Registry
clinicaltrials.gov
Start Date
May 2007
End Date
December 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Kessler Foundation
Responsible Party
Principal Investigator
Principal Investigator

A. M. Barrett, MD

Director, Stroke Rehabilitation Research

Kessler Foundation

Eligibility Criteria

Inclusion Criteria

  • I am 18 to100 yrs old.
  • I had one stroke 4 months to 5 yrs ago
  • I am not taking Aricept or other cholinesterase inhibitors (e.g. Exelon, Razadyne) or memantine (Namenda).

Exclusion Criteria

  • I have history of dementia and or have been diagnosed with a memory disorder prior to my stroke.
  • I have been on anti-depressants or other cognitive enhancing drugs for less than 3 months and the dose is not stabilized yet.
  • I consume alcohol more than or equivalent of 4 ounces hard liquor weekly.
  • I am taking oral anticholinergic medications like Bethanechol, Bentyl or Detrol.
  • I am a woman of childbearing potential or I am pregnant or a nursing mother.
  • I have a history of chronic vomiting or diarrhea.
  • I am allergic to Aricept.

Arms & Interventions

Aricept- A

Half of subjects are randomized to immediate treatment with donepezil 5mg orally daily following baseline testing, with retesting at 12 and 24 weeks.

Intervention: Donepezil and self-generated memory training

Aricept- A

Half of subjects are randomized to immediate treatment with donepezil 5mg orally daily following baseline testing, with retesting at 12 and 24 weeks.

Intervention: Donepezil and experimenter-administered memory training

A2-12-week waiting period

The remaining nine subjects are randomized to testing followed by a 12-week waiting period. After the 12 week wait, this group of subjects is retested and begins taking donepezil, 5 mg orally daily, with retesting at 24 weeks

Intervention: Donepezil and self-generated memory training

A2-12-week waiting period

The remaining nine subjects are randomized to testing followed by a 12-week waiting period. After the 12 week wait, this group of subjects is retested and begins taking donepezil, 5 mg orally daily, with retesting at 24 weeks

Intervention: Donepezil and experimenter-administered memory training

Outcomes

Primary Outcomes

Primary: To examine whether taking Aricept results in improvement at remembering steps of functional tasks.

Time Frame: 12 weeks

Secondary Outcomes

  • To examine whether taking Aricept and actually performing functional tasks improves memory over that provided by a self-generation strategy.(24 weeks)

Study Sites (1)

Loading locations...

Similar Trials